
What’s Ahead for Alzheimer’s Drugs in 2025
Learn about 2025’s newly approved or potential Alzheimer’s drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.

Learn about 2025’s newly approved or potential Alzheimer’s drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.

Leqembi and Kisunla are the new Alzheimer’s immunotherapies. A loss of brain volume associated with these immunotherapies may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue. A new study sheds light on what’s going on.

A trio of key studies identified predictors of dementia risk, the benefits of detecting cognitive impairment early and identified barriers to routine cognitive screening in older adults, such as cost. See their recommendations.

How much protection can frequent spatial processing tasks offer against Alzheimer’s? Researchers in The British Medical Journal investigate.

A new study shows ultrasound improves memory even when amyloid plaque levels don’t improve. (Amyloid is the culprit behind Alzheimer’s.) Could ultrasound be the missing piece in the Alzheimer’s puzzle?

Ketones are a backup source of energy for neurons. Now, exciting research reveals bigger news: Ketone esters help clear misfolded proteins in animal models of aging and Alzheimer’s.

Europe originally said Lecanemab (Brand-name Leqembi) was too risky to approve. Now they are recommending marketing it. Why the change of heart?

Japanese researchers develop a simple test for diagnosing Alzheimer’s quickly, easily, with 83% accuracy.

The European Medicines Agency (EMA) recommended approving Leqembi® (generic lecanemab) for Alzheimer’s. Originally skeptics, learn how the “Clarity AD” trial helped change their mind.

See Lady Liv, the first AI avatar born from real people’s lived experiences with dementia. Watch ‘Liv’ help those recently diagnosed, by answering questions only a peer who shares the experience of Alzheimer’s would know.

COCHRANE SERIES, PART 3 – DEEP DIVE: False alarm. The Cochrane Review shook confidence in Leqembi. It rests on a scientific threshold its own source publicly disowned. Here’s why the evidence did not justify the alarm.

When we honestly ask ourselves, which person in our lives means the most to us, We find that it is those who have chosen to

COCHRANE SERIES, PART 2 – HOW IT HAPPENED: A new review just went viral in the media, declaring Alzheimer’s drugs don’t work. Leading scientists say the methodology was fundamentally flawed.

An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?

Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!

It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.

TEEPA CARE VIDEO: Learn about Alzheimer’s 6 stages. Teepa Snow shows what to expect, while keeping the focus on the person for whom you care.
No spam, only news and updates.



We use cookies and similar technologies to improve your experience, understand how our content is used, and support relevant advertising that helps keep Alzheimer’s Weekly free to readers. You can choose to accept, deny, or manage your preferences at any time. Declining certain cookies may affect features such as embedded videos, comments, and personalized advertising.